FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105462887> ?p ?o ?g. }

• W2105462887 abstract "Abstract Background Simultaneous PET/MR imaging depends on MR-derived attenuation maps (mu-maps) for accurate attenuation correction of PET data. Currently, these maps are derived from gradient-echo-based MR sequences, which are sensitive to susceptibility changes. Iron oxide magnetic nanoparticles have been used in the measurement of blood volume, tumor microvasculature, tumor-associated macrophages, and characterizing lymph nodes. Our aim in this study was to assess whether the susceptibility effects associated with iron oxide nanoparticles can potentially affect measured 18 F-FDG PET standardized uptake values (SUV) through effects on MR-derived attenuation maps. Methods The study protocol was approved by the Institutional Animal Care and Use Committee. Using a Siemens Biograph mMR PET/MR scanner, we evaluated the effects of increasing concentrations of ferumoxytol and ferumoxytol aggregates on MR-derived mu-maps using an agarose phantom. In addition, we performed a baboon experiment evaluating the effects of a single i.v. ferumoxytol dose (10 mg/kg) on the liver, spleen, and pancreas 18 F-FDG SUV at baseline (ferumoxytol-naïve), within the first hour and at 1, 3, 5, and 11 weeks. Results Phantom experiments showed mu-map artifacts starting at ferumoxytol aggregate concentrations of 10 to 20 mg/kg. The in vivo baboon data demonstrated a 53% decrease of observed 18 F-FDG SUV compared to baseline within the first hour in the liver, persisting at least 11 weeks. Conclusions A single ferumoxytol dose can affect measured SUV for at least 3 months, which should be taken into account when administrating ferumoxytol in patients needing sequential PET/MR scans. Advances in knowledge 1. Ferumoxytol aggregates, but not ferumoxytol alone, produce significant artifacts in MR-derived attenuation correction maps at approximate clinical dose levels of 10 mg/kg. 2. When performing simultaneous whole-body 18 F-FDG PET/MR, a single dose of ferumoxytol can result in observed SUV decreases up to 53%, depending on the amount of ferumoxytol aggregates in the studied tissue. Implications for patient care Administration of a single, clinically relevant, dose of ferumoxytol can potentially result in changes in observed SUV for a prolonged period of time in the setting of simultaneous PET/MR. These potential changes should be considered in particular when administering ferumoxytol to patients with expected future PET/MR studies, as ferumoxytol-induced SUV changes might interfere with therapy assessment." @default.
• W2105462887 created "2016-06-24" @default.
• W2105462887 creator A5004268054 @default.
• W2105462887 creator A5022933070 @default.
• W2105462887 creator A5024433006 @default.
• W2105462887 creator A5026299628 @default.
• W2105462887 creator A5033899634 @default.
• W2105462887 creator A5044303900 @default.
• W2105462887 creator A5044512666 @default.
• W2105462887 creator A5046001363 @default.
• W2105462887 creator A5048153659 @default.
• W2105462887 creator A5073383259 @default.
• W2105462887 date "2015-02-26" @default.
• W2105462887 modified "2023-10-14" @default.
• W2105462887 title "Effects of ferumoxytol on quantitative PET measurements in simultaneous PET/MR whole-body imaging: a pilot study in a baboon model" @default.
• W2105462887 cites W1548133588 @default.
• W2105462887 cites W1974023961 @default.
• W2105462887 cites W1991035308 @default.
• W2105462887 cites W1992693587 @default.
• W2105462887 cites W2000486133 @default.
• W2105462887 cites W2002129123 @default.
• W2105462887 cites W2035408744 @default.
• W2105462887 cites W2036005195 @default.
• W2105462887 cites W2036392014 @default.
• W2105462887 cites W2038867401 @default.
• W2105462887 cites W2047702914 @default.
• W2105462887 cites W2050298314 @default.
• W2105462887 cites W2057792406 @default.
• W2105462887 cites W2059756358 @default.
• W2105462887 cites W2063208162 @default.
• W2105462887 cites W2070305242 @default.
• W2105462887 cites W2091895824 @default.
• W2105462887 cites W2102614983 @default.
• W2105462887 cites W2128857039 @default.
• W2105462887 cites W2140479375 @default.
• W2105462887 cites W2142082007 @default.
• W2105462887 cites W2150041194 @default.
• W2105462887 cites W2161971256 @default.
• W2105462887 cites W2163203871 @default.
• W2105462887 cites W2171939783 @default.
• W2105462887 cites W2317019069 @default.
• W2105462887 doi "https://doi.org/10.1186/s40658-015-0109-0" @default.
• W2105462887 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4544618" @default.
• W2105462887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26501808" @default.
• W2105462887 hasPublicationYear "2015" @default.
• W2105462887 type Work @default.
• W2105462887 sameAs 2105462887 @default.
• W2105462887 citedByCount "10" @default.
• W2105462887 countsByYear W21054628872016 @default.
• W2105462887 countsByYear W21054628872017 @default.
• W2105462887 countsByYear W21054628872019 @default.
• W2105462887 countsByYear W21054628872020 @default.
• W2105462887 countsByYear W21054628872022 @default.
• W2105462887 countsByYear W21054628872023 @default.
• W2105462887 crossrefType "journal-article" @default.
• W2105462887 hasAuthorship W2105462887A5004268054 @default.
• W2105462887 hasAuthorship W2105462887A5022933070 @default.
• W2105462887 hasAuthorship W2105462887A5024433006 @default.
• W2105462887 hasAuthorship W2105462887A5026299628 @default.
• W2105462887 hasAuthorship W2105462887A5033899634 @default.
• W2105462887 hasAuthorship W2105462887A5044303900 @default.
• W2105462887 hasAuthorship W2105462887A5044512666 @default.
• W2105462887 hasAuthorship W2105462887A5046001363 @default.
• W2105462887 hasAuthorship W2105462887A5048153659 @default.
• W2105462887 hasAuthorship W2105462887A5073383259 @default.
• W2105462887 hasBestOaLocation W21054628871 @default.
• W2105462887 hasConcept C104293457 @default.
• W2105462887 hasConcept C126322002 @default.
• W2105462887 hasConcept C126838900 @default.
• W2105462887 hasConcept C143409427 @default.
• W2105462887 hasConcept C150903083 @default.
• W2105462887 hasConcept C207001950 @default.
• W2105462887 hasConcept C2779594886 @default.
• W2105462887 hasConcept C2909801847 @default.
• W2105462887 hasConcept C2989005 @default.
• W2105462887 hasConcept C71924100 @default.
• W2105462887 hasConcept C86803240 @default.
• W2105462887 hasConceptScore W2105462887C104293457 @default.
• W2105462887 hasConceptScore W2105462887C126322002 @default.
• W2105462887 hasConceptScore W2105462887C126838900 @default.
• W2105462887 hasConceptScore W2105462887C143409427 @default.
• W2105462887 hasConceptScore W2105462887C150903083 @default.
• W2105462887 hasConceptScore W2105462887C207001950 @default.
• W2105462887 hasConceptScore W2105462887C2779594886 @default.
• W2105462887 hasConceptScore W2105462887C2909801847 @default.
• W2105462887 hasConceptScore W2105462887C2989005 @default.
• W2105462887 hasConceptScore W2105462887C71924100 @default.
• W2105462887 hasConceptScore W2105462887C86803240 @default.
• W2105462887 hasIssue "1" @default.
• W2105462887 hasLocation W21054628871 @default.
• W2105462887 hasLocation W21054628872 @default.
• W2105462887 hasLocation W21054628873 @default.
• W2105462887 hasLocation W21054628874 @default.
• W2105462887 hasLocation W21054628875 @default.
• W2105462887 hasLocation W21054628876 @default.
• W2105462887 hasLocation W21054628877 @default.
• W2105462887 hasOpenAccess W2105462887 @default.
• W2105462887 hasPrimaryLocation W21054628871 @default.
• W2105462887 hasRelatedWork W1990725810 @default.
• W2105462887 hasRelatedWork W1991183903 @default.

• next